Nebraska Oncology Society 23rd Annual Midwest Regional ASCO Review 2022

20 $

‘+ Include: 15 videos + 1 pdf, size: 1.33 GB

+ Target Audience: oncologist

Description

+ Include: 15 videos + 1 pdf, size: 1.33 GB

+ Target Audience: oncologist

+ Sample video: contact me for sample video

+ Information:

No information

 

 

+ Topics:

asco_agenda_2022-website.pdf
Early Stage NSCLC Reported and Ongoing Phase 3 Neoadjuvant Chemo and or IO Trials.ts
Head and Neck Cancer Update.ts
HR Breast Cancer Updates.ts
Immunotherapy Updates in Advanced NSCLC.ts
Locally Advanced NSCLC.ts
Moving Toward a Cure in Myeloma The Role of MRD Testing.ts
Phase 3 DESTINY-Breast 03 Trial HER2+ BC Updates.ts
Phase 3 KEYNOTE-522 Trial TNBC Updates.ts
SCLC Updates IO+Chemo Combinations Remain the Standard of Care.ts
Surgically Resectable NSCLC Updates From the Adjuvant IO Trials.ts
Updates on Colon Cancer Treatment.ts
Updates on GI Cancers Pancreatic, Gastric, Bile Duct, and Neuroendocrine.ts
Updates on Molecular Based Imaging for Prostate Cancer Redefining the Disease Landscape.ts
Updates on RAS BRAF KRAS NRAS Wild-Type mCRC Summary of Recent Trials.ts
Updates on Rectal Cancer Treatment.ts

Reviews

There are no reviews yet.

Be the first to review “Nebraska Oncology Society 23rd Annual Midwest Regional ASCO Review 2022”

Your email address will not be published. Required fields are marked *